Zietchick Research Institute, LLC

Biotech · Private

Hormone-enriched therapeutic (hCG/LH-based) for retinopathy of prematurity prevention in premature infants

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$450K
Federal grants
$450K
2 awards · 2016–2017
Rank in peer group#310 of 502
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
5 pending

Capital timeline

20162017FEDERAL ↑EQUITY ↓Cumulative $450K$225K$225K
20162017FEDERAL ↑EQUITY ↓Cumulative $450K$225K$225K

Latest events

  • Federal grantHealth and Human S · Phase I · Hormonal Therapeutic for Retinopathy of Prematurity$225K
  • Federal grantHealth and Human S · Phase I · Development of a Novel Therapeutic for Diabetic Retinopathy$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 5
  • PendingMethod For Monitoring Fetus/preterm Infant Development, And For Promoting The Normal Development Of Preterm InfantsUSPTOApplication 16096258
  • PendingMethod For Preventing Or Treating Ocular DisordersUSPTOApplication 15322881
  • PendingMethod For Monitoring Fetus/preterm Infant Development, And For Promoting The Normal Development Of Preterm InfantsUSPTOApplication PCTUS2017029880
Show all 5 patent records
  • Method For Monitoring Fetus/preterm Infant Development, And For Promoting The Normal Development Of Preterm InfantsMay 30, 2019 · Application 16096258Pending
  • Method For Preventing Or Treating Ocular DisordersMay 18, 2017 · Application 15322881Pending
  • Method For Monitoring Fetus/preterm Infant Development, And For Promoting The Normal Development Of Preterm InfantsApplication PCTUS2017029880Pending
  • Method For Preventing Or Treating Ocular DisordersApplication PCTUS2015039542Pending
  • Method to Prevent Progression of Ocular Disorders involving Neovascularization (such as Diabetic Retinopathy, Age-Related Macular Degeneration, Retinopathy of Prematurity) Utilizing Human Chorionic Gonadotropin AntagonistsApplication 62024609Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .